Contributions
Abstract: PB1545
Type: Publication Only
Session title: Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research
Background
Galway University Hospital (GUH) is the designated cancer centre for the west of Ireland. It has strong links with the National University of Ireland, Galway (NUIG) for training and research. The Blood Cancer Network Ireland (BCNI) established a biobank in NUIG in 2017. With the collaboration of GUH and NUIG, biobanking of peripheral blood and bone marrow aspirate commenced in Galway that same year. Bone marrow procedures are carried out daily in GUH for the diagnosis of haematological disorders. After obtaining informed patient consent, additional bone marrow aspirate and peripheral blood samples for BCNI biobanking are collected at the patient bedside. These samples are transported to NUIG, then processed and stored in the BCNI biobank for future research.
Aims
To establish a blood cancer biobank for use in early phase clinical trials. To optimise sample collection and transport to ensure the integrity of the biobanked sample.
Methods
Implementation involved multidisciplinary collaborations including researchers, consultant haematologists, haematology registrars, advanced nurse practitioner and medical scientists at the BCNI, Galway and the Department of Haematology, GUH. Staff educational sessions were provided by the BCNI. Bone marrow procedures were performed by haematology registrars or the advanced nurse practitioner at GUH. Patient consent for biobanking was obtained prior to the bone marrow proceedure and informational leaflets provided to each patient. The medical scientist ensured that the bone marrow aspirate sample was adequate for the evaluation of the patient's haematological condition and then collected additional samples for biobanking. On return to the Haematology Laboratory the medical scientist arranged transport to the BCNI laboratory in a timely manner, to ensure sample integrity. Samples were processed and stored in the BCNI biobank at NUIG.
Results
Currently, 448 samples have been collected and stored in biobanks at BCNI sites across Ireland. Of these, 62 samples have been provided through the Department of Haematology, GUH. The majority of samples collected have been from patients with Acute Myeloid Leukaemia (AML).
Conclusion
The implementation of biobanking in GUH has been successful to date. Biobanking has now expanded to include the collection of samples from patients with Monoclonal Gammopathy of Undetermined Significance (MGUS). Additional educational sessions are required to increase awareness of biobanking to all relevant staff in GUH, in order to optimise the collection of samples. Improvement of quality control measures to ensure optimal transport and storage of cells from GUH to NUIG is also required.
Keyword(s): Bone Marrow
Abstract: PB1545
Type: Publication Only
Session title: Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research
Background
Galway University Hospital (GUH) is the designated cancer centre for the west of Ireland. It has strong links with the National University of Ireland, Galway (NUIG) for training and research. The Blood Cancer Network Ireland (BCNI) established a biobank in NUIG in 2017. With the collaboration of GUH and NUIG, biobanking of peripheral blood and bone marrow aspirate commenced in Galway that same year. Bone marrow procedures are carried out daily in GUH for the diagnosis of haematological disorders. After obtaining informed patient consent, additional bone marrow aspirate and peripheral blood samples for BCNI biobanking are collected at the patient bedside. These samples are transported to NUIG, then processed and stored in the BCNI biobank for future research.
Aims
To establish a blood cancer biobank for use in early phase clinical trials. To optimise sample collection and transport to ensure the integrity of the biobanked sample.
Methods
Implementation involved multidisciplinary collaborations including researchers, consultant haematologists, haematology registrars, advanced nurse practitioner and medical scientists at the BCNI, Galway and the Department of Haematology, GUH. Staff educational sessions were provided by the BCNI. Bone marrow procedures were performed by haematology registrars or the advanced nurse practitioner at GUH. Patient consent for biobanking was obtained prior to the bone marrow proceedure and informational leaflets provided to each patient. The medical scientist ensured that the bone marrow aspirate sample was adequate for the evaluation of the patient's haematological condition and then collected additional samples for biobanking. On return to the Haematology Laboratory the medical scientist arranged transport to the BCNI laboratory in a timely manner, to ensure sample integrity. Samples were processed and stored in the BCNI biobank at NUIG.
Results
Currently, 448 samples have been collected and stored in biobanks at BCNI sites across Ireland. Of these, 62 samples have been provided through the Department of Haematology, GUH. The majority of samples collected have been from patients with Acute Myeloid Leukaemia (AML).
Conclusion
The implementation of biobanking in GUH has been successful to date. Biobanking has now expanded to include the collection of samples from patients with Monoclonal Gammopathy of Undetermined Significance (MGUS). Additional educational sessions are required to increase awareness of biobanking to all relevant staff in GUH, in order to optimise the collection of samples. Improvement of quality control measures to ensure optimal transport and storage of cells from GUH to NUIG is also required.
Keyword(s): Bone Marrow